pioneer 4 semaglutide Oral Lowers HbA1c in Phase 3 Trial in Youth With Type 2 Diabetes Efficacy, safety and cardiovascular outcomes

Key Differences Summary# Conclusion# Liraglutide represents a meaningful advancement over exenatide across glycemic control (LEAD-6 and DURATION-6 head-to-head superiority), weight management (only agent with FDA obesity approval among the two), cardiovascular outcomes (LEADER superiority vs EXSCEL non-inferiority), and tolerability (less persistent nausea, no injection site nodules, minimal immunogenicity)

The injection is also approved for weight management in adolescents 12 and older with obesity

Effects of lixisenatide once daily on gastric emptying in type 2 diabetesrelationship to postprandial glycemia

Type I, or slow-twitch, muscle fibers are equipped with the mitochondria and enzymatic machinery for cellular respiration

the most frequently reported reactions were nausea, vomiting, and diarrhea